Phaseline

Companies › Lion TCR Pte.

Lion TCR Pte.: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LioCyx-M
HBV antigen-specific TCR-redirected autologous T cells
–Phase 1Hepatocellular CarcinomaDec 2027
mRNA HBV/TCR T-cells
mRNA-engineered T cells redirected to recognize HBV-specific epitopes
–Phase 1Hepatocellular CarcinomaJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06961617LioCyx-MPhase 1Hepatocellular CarcinomaOncologyDec 2027
NCT04745403mRNA HBV/TCR T-cellsPhase 1Hepatocellular CarcinomaOncologyJul 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.